Clinical trial · Interventional
Yang Yin Fu Zheng Therapy in HBV Associated Hepatocellular Carcinoma
Clinical Research of Yang Yin Fu Zheng Therapy in HBV Associated Hepatocellular Carcinoma Basing on Immune Microenviroment
NCT02927626CI-TRIAL-00045901YYFZTIHBVHCCcompletedEarly Phase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Clinical research of Yang Yin Fu Zheng therapy in HBV associated hepatocellular carcinoma basing on immune microenviroment.The purpose of this study is to observe the efficacy of routine medical care combined with Yang Yin Fu Zheng therapy for patients belong to HBV-HCC.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Routine medical care | Drug | — | UNRESOLVED |
| Yang Yin Fu Zheng therapy | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Yang Yin Fu Zheng therapy
- interventionNames
- Drug: Yang Yin Fu Zheng therapy
- Drug: Routine medical care
- type
- PLACEBO_COMPARATOR
- label
- Routine medical care
- interventionNames
- Drug: Routine medical care
Primary outcomes (1)
- measure
- Survival rate
- timeFrame
- 2 years
Secondary outcomes (2)
- measure
- Objective response rate
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1. Confirmed of stage HBV-HCCⅡb、Ⅲa、Ⅲb; 2. Ages Eligible for Study: ≤75 years old; 3. TCM syndrome is deficiency of both Qi and Yin; 4. Confirmed of CHB; 5. Surgery cannot be allowed; 6. Informed consent from the patient. Exclusion Criteria: 1. Patient with other chronic hepatopathy, such as AIH, NAFLD, ALD; 2. Serious problem of heart, lung, or kidney with severe dysfunction; 3. Pregnant or child breast feeding women; 4. Mental or cognitive disorders; 5. Participating in other drug trials; 6. Who are allergic to the study drug.
References
Publications (0)
Data not yet available
No reference posted for this study.